Daewoong Pioneers First-Ever NK Cell Technology Transfer to Indonesia, Advancing Anti-Cancer Treatment

Writer

Manager

June 21, 2025

Daewoong Pioneers First-Ever NK Cell Technology Transfer to Indonesia, Advancing Anti-Cancer Treatment

- Opening a New Era of NK Cell Therapyin Indonesia: From No Options to Advanced Solutions

- Daewoong’s differentiated Technology enables high-quality NK cell production

- Hope for Cancer Patients: Indonesia Gains Access to Innovative Cancer Treatments with Daewoong's NK Cell Therapy

(Jakarta, 15 January 2025)

(Jakarta, 15 January 2025) Daewoong transfers advanced NK cell technology to Indonesia, marking amilestone in anti-cancer treatment in Indonesia.

Daewoong has announced thesuccessful transfer of cutting-edge natural killer (NK) cell technology toIndonesia, installing the country's first-ever GMP-grade NK cell technology atDaewoong Biologics Indonesia, a Daewoong affiliate.

This groundbreaking initiative includes the transfer of GMP-grade NK cell manufacturing andanalysis techniques and method validation, storage and transportation methods,and commercialization strategies, solidifying the foundation for advanced regenerative medicine in Indonesia.

Prior to this transfer,Indonesia had no local production of GMP-approved NK cell therapies, severelyrestricting access to innovative cancer treatments. This transfer introduces,for the first time, the production and supply of high-quality NK celltherapies, catalyzing Indonesia's oncology market and offering cutting-edgetreatment options to cancer patients in need.

Daewoong's proprietary NKcell manufacturing technology, implemented at Daewoong Biologics Indonesia'sfacility, exhibits unique strengths in mass production while prioritizing cellactivity and safety. Unlike conventional methods that rely on feeder cells,which pose potential safety concerns, Daewoong's innovative approach offers asignificant technological advantage, enhancing quality.

Specifically, in terms ofquality, Daewoong's NK cells demonstrate an average cell viability of 95%,underpinned by high expression of surface markers and genes associated with anti-cancer activity. In terms of productivity, this is facilitated by a uniquestimulator. This eliminates the need for feeder cells while achievingproduction levels comparable to, and even exceeding, those obtained usingfeeder cells.

This initiative underscores Daewoong's commitment to expanding the reach of advanced regenerative medicaltechnology globally, as part of its vision to provide innovative NK cell therapies. Leveraging its advanced manufacturing skills and production know-how, Daewoong Pharmaceutical is set to create sustainable environments for producing high-quality cell therapies in regions facing shortages.

Baik In Hyun, Head ofDaewoong Biologics Indonesia’s business unit stated that "As highlightedin a recent OECD report, cancer remains the third leading cause of mortality inIndonesia. The integration of advanced NK cell therapies represents asignificant step toward improving patient outcomes and reducing cancer-relatedmortality" and "We are committed to leveraging this innovativetechnology to not only enhance the quality of cancer care in Indonesia but alsoset a new benchmark for personalized treatments in the region.”

Daewoong Biologics Indonesiaplans to solidify its leadership in the cutting-edge cell therapy market byestablishing stable production and supply systems. This transfer is not justabout importing technology but also about sparking growth in Indonesia'sbiopharmaceutical industry and enhancing local cancer treatment standards.Moreover, there is an ambition to enter global markets, using innovative celltherapies to improve the quality of life for cancer patients worldwide. Drivenby ongoing research and development, Daewoong Biologics Indonesia is poised tolead the regenerative medicine sector while advancing its vision to become aglobal healthcare frontrunner.

For over two decades,Daewoong has been deeply committed to fostering shared growth with Indonesiasince the opening of its Jakarta branch in 2005. In 2012, Daewoong furthersolidified its dedication by establishing Daewoong Infion, Indonesia’s firstbiopharmaceutical production facility, facilitating technology transfer forbiopharmaceutical manufacturing and offering Halal-certified EPO and EGFmedicines. Daewoong’s EPO API quickly secured a dominant market share withinsix months of its Indonesian launch and is now exported to South Korea. Tofortify local production capabilities, Daewoong completed the construction of astate-of-the-art stem cell therapy facility in Indonesia in 2024. This 20-yearjourney exemplifies Daewoong’s unwavering commitment to mutual growth andinnovation in partnership with Indonesia.

- # # # -

‍

list

Daewoong Pioneers First-Ever NK Cell Technology Transfer to Indonesia, Advancing Anti-Cancer Treatment

‍

Privacy Policy

이용약관